HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VTP-43742

inhibits retinoic acid receptor-related orphan nuclear receptor gamma t; structure in first source

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - VTP-43742: 4
  - Pyridines: 88
    - VTP-43742: 4

Experts

1.	Assani, Israa: 1 article (01/2022)
2.	Chen, Hong-Wu: 1 article (01/2022)
3.	Chen, Lei: 1 article (01/2022)
4.	Jin, Qiu: 1 article (01/2022)
5.	Li, Yan: 1 article (01/2022)
6.	Liao, Zhi-Xin: 1 article (01/2022)
7.	Liu, Ruiwu: 1 article (01/2022)
8.	Lv, Shen-Min: 1 article (01/2022)
9.	Shi, Zhenrui: 1 article (01/2022)
10.	Su, Mei: 1 article (01/2022)

Related Diseases

1.	Lymphoma (Lymphomas) 12/01/2021 - "Main reasons were lack of efficacy (topical) or safety signals (oral) as well as, amongst other things, thymic lymphomas as seen with BMS-986251 in a preclinical study and liver enzyme elevations in humans with VTP-43742. "
2.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2022 - "Clinical proof-of-concept (PoC) with small molecule inverse agonists of RORγt has been achieved with VTP-43742 (Phase II) for the treatment of psoriasis, and pre-clinical PoC for this mechanism has also been established for the treatment of autoimmune diseases. " 12/27/2018 - "With the clinical proof-of-concept inferred from a small molecule inhibitor VTP-43742 for psoriasis and recent inflow of several RORc inhibitors into the clinic for therapeutic interventions in autoimmune diseases, this field continues to evolve. "
3.	Autoimmune Diseases (Autoimmune Disease) 01/01/2022 - "Clinical proof-of-concept (PoC) with small molecule inverse agonists of RORγt has been achieved with VTP-43742 (Phase II) for the treatment of psoriasis, and pre-clinical PoC for this mechanism has also been established for the treatment of autoimmune diseases. " 12/27/2018 - "With the clinical proof-of-concept inferred from a small molecule inhibitor VTP-43742 for psoriasis and recent inflow of several RORc inhibitors into the clinic for therapeutic interventions in autoimmune diseases, this field continues to evolve. "
4.	Neoplasms (Cancer) 01/01/2022 - "We report here that inverse agonists/antagonists of RORγ such as VTP-43742 derivative VTP-23 and TAK828F, which can potently inhibit the inflammatory gene program in Th17 cells, unexpectedly lack high potency in inhibiting the growth of TNBC tumor cells. "

Related Drugs and Biologics

1.	Enzymes